<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221021056258N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-13</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Biological and Pharmacological Activities Of Squalene In Acute Myocardial Infarction</public_title>
      <acronym></acronym>
      <scientific_title>Biological and Pharmacological Activities Of Squalene,Potential Uses In Acute Myocardial Infarction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66463</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, the random sequence is generated using www.randomization.com.
Then, based on the size of the research sample, a number of envelopes with aluminum wrappers (in order not to make the contents of the envelopes unclear) are prepared and each of the random sequences created is recorded on a card and the cards are placed inside the envelopes.
In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lids of the envelopes are glued and placed in a box. At the time of patient sampling, based on the order of entry of eligible participants into the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: Acute myocardial infarction. Condition 2: Heart failure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to routine treatments, the group receiving squalene drops will receive sublingually and 4 times a day with a dose of 5 drops each time for 5 days. The concentration of the drug is ten milligrams per milliliter and with It is produced by the collaboration of Mashhad Faculty of Medical Sciences and professors of pharmacy and chemical engineers of the Faculty of Basic Sciences of Ferdowsi University of Mashhad.Squalene extracted from vegetable oils is a non-toxic and biocompatible lipid that has various applications in the food and pharmaceutical industries. Also, this compound is a precursor of cholesterol and one of the natural components of human skin and protects it against radiation. So far, its anti-inflammatory, antioxidant and anti-tumor properties have been investigated and proven in animal studies, and no toxicity and or adverse effects have not been reported in animals. Intervention 2: Control group: Only recipients of routine treatments for acute myocardial infarction and heart failure.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is We do not have a plan to publish yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza fazeli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 5, Saremi Ave., Vakilabad Blvd., Mashhad Town</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>476876543564</zip>
        <telephone>+98 51 3843 5676</telephone>
        <email>fazelia981@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza fazeli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 5, Saremi Ave., Vakil abad Blvd., Mashhad Town</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6547698743</zip>
        <telephone>+98 51 3832 4567</telephone>
        <email>fazelia981@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18 to 80 years old
Patients who have been diagnosed with ST segment elevation myocardial infarction and have undergone successful vascularization with angioplasty in the vessel related to the infarct.
Ejection fraction less than forty percent in the field of acute Myocardial infarction</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Ventricular arrhythmia
Congenital heart disease
Suspected or documented history of heart failure or decreased ejection fraction (EF) of the left ventricle
CABG candidate patients or previous CABG history
GFR less than 30
People with autoimmune diseases or connective tissue disease
People with cancer
Pregnant and lactating women
Psychiatric patients and people who cannot complete the one-month clinical follow-up during the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I21.0</hc_code>
      <hc_code>I50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>ST elevation (STEMI) myocardial infarction of anterior wall</hc_keyword>
      <hc_keyword>Heart failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to routine treatments, the group receiving squalene drops will receive sublingually and 4 times a day with a dose of 5 drops each time for 5 days. The concentration of the drug is ten milligrams per milliliter and with It is produced by the collaboration of Mashhad Faculty of Medical Sciences and professors of pharmacy and chemical engineers of the Faculty of Basic Sciences of Ferdowsi University of Mashhad.Squalene extracted from vegetable oils is a non-toxic and biocompatible lipid that has various applications in the food and pharmaceutical industries. Also, this compound is a precursor of cholesterol and one of the natural components of human skin and protects it against radiation. So far, its anti-inflammatory, antioxidant and anti-tumor properties have been investigated and proven in animal studies, and no toxicity and or adverse effects have not been reported in animals.</i_keyword>
      <i_keyword>Control group: Only recipients of routine treatments for acute myocardial infarction and heart failure.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ejection fraction. Timepoint: Patients undergo  echocardiography in the first 24 hours before starting the drug and then after 30 days. Method of measurement: Echocardiography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wall motion abnormality. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Diastolic dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Pulmonary arterial pressure. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Valvular Dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Laboratory factors such as complete blood cell count. Timepoint: Before starting the drug and after thirty days from the start of the drug. Method of measurement: Laboratory kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-11</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Imam reza hospital., Ahmadabad Blvd., Mashhad Town Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
